SecBot SecBot
8-K ·Filed Aug 11, 2026

CCCC

C4 Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0001628280-26-055490
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming catalysts: Phase 1b dose escalation update in 2H 2026 and IMS biomarker data in September 2026. The extended cash runway reduces near-term financing risk, but ATM dilution and lack of product revenue keep the stock dependent on clinical milestones.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.87
T+0 close · Aug 11, 2026 · via day close
Latest settled
−20.03%
T+60 · $3.10
Vs SPY
−19.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $3.87entry
  2. T+1 · 3mo ago +0.78%α +0.52% · $3.90
  3. T+5 · 3mo ago +8.01%α +8.41% · $4.18
  4. T+20 · 2mo ago −11.11%α −10.05% · $3.44
  5. T+60 · 13d ago −20.03%α −19.89% · $3.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

C4 Therapeutics reported Q2 2026 revenue of $6.6M (up 2.7% YoY) and a net loss of $23.6M ($0.18 per share), beating the Street consensus of -$0.23 by 21.7%. Cash increased to $300.4M following a $33.5M ATM raise and $20M Roche upfront, extending runway to end 2028. Clinical progress remains on track with Phase 2 MOMENTUM enrollment expected to complete in Q1 2027 and data in 2H 2027.

Key Financial Metrics

EPS
−$0.18
est −$0.23 · +21.7%
Revenue
$6.6M
+2.8% YoY
Rating
beat

Key Facts

  • Q2 2026 revenue $6.6M vs $6.5M YoY (up 2.7%)
  • Net loss $23.6M vs $26.0M YoY; EPS -$0.18 vs -$0.37 YoY
  • EPS beat consensus of -$0.23 by 21.7%
  • Cash $300.4M, up from $268.3M QoQ; runway to end 2028
  • Raised $33.5M net via ATM program in Q2
  • Received $20M upfront from Roche DAC collaboration
  • Phase 2 MOMENTUM trial on track to complete enrollment Q1 2027, data 2H 2027
  • Phase 1b with elranatamab progressing; update expected 2H 2026
  • EHA data showed 40% ORR at 75µg and 53% ORR at 100µg cemsidomide doses

Financial Impact

EPS beat of $0.05 per share (21.7%) on consensus of -$0.23; revenue slightly above prior year; cash position strengthened by $33.5M ATM and $20M Roche upfront

epscashrevenue

Risk Factors

  • Dilution from ongoing ATM program
  • Clinical trial risk for cemsidomide (Phase 2 MOMENTUM and Phase 1b combinations)
  • No approved products; revenue entirely from collaborations
  • Competition from approved IKZF1/3 degraders and other MM therapies

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-055490
Document: cccc-20260811.htm0001628280-26-055490
Document: 0001628280-26-055490-index-headers.html0001628280-26-055490
Document: 0001628280-26-055490-index.html0001628280-26-055490
Document: 0001628280-26-055490.txt0001628280-26-055490
8-K Data (Synthetic)0001628280-26-055490

Track record

19 reports on CCCC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
  6. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  7. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  8. Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  9. Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  10. Aug 11, 202613w ago 8-K Neutral 5/10 Viewing Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026